Obesity-drug power couple Novo Nordisk and Eli Lilly still have room to run, analysts say

Novo Nordisk and Eli Lilly, the dynamic duo of the weight-loss drug world, still have plenty of upside even after their shares have surged over the past 12 months, analysts say.

Previous post Bernanke recommends Bank of England axe ‘fan charts’ but not use dot plot
Next post Nvidia just keeps getting stronger, and that could be trouble for this stock